Equillium doses first subject in Phase 1 trial of oral inflammation drug EQ504
Equillium Inc. dosed the initial participant in its Phase 1 study of EQ504, an oral colon‑targeted aryl hydrocarbon receptor modulator, in Australia. The trial will assess safety, tolerability, pharmacokinetics and pharmacodynamics in about 70 healthy volunteers, with doses ranging from 0.1 mg to 3.0 mg. Topline data are expected in the second quarter of 2027, and, if supportive, a placebo‑controlled proof‑of‑concept study in ulcerative colitis patients is planned for the second half of 2027. The dosing event also activates a $20 million closing of the August 2025 equity private placement, bringing total proceeds to roughly $50 million and extending cash runway to 2029.
Why it matters
The $20 million infusion, together with existing cash, is expected to fund Equillium’s operations through 2029, according to the company. Successful Phase 1 results could enable a pivotal ulcerative colitis study in late 2027, potentially advancing the drug toward market approval.
Key facts
- 1Equillium dosed the first subject in the Phase 1 trial of EQ504 in Australia. stocktitan.net
- 2The trial will enroll approximately 70 healthy subjects and test once‑daily oral doses from 0.1 mg to 3.0 mg. stocktitan.net
- 3Topline Phase 1 data are anticipated in Q2 2027. stocktitan.net
- 4If Phase 1 data are supportive, a placebo‑controlled proof‑of‑concept study in ulcerative colitis patients is planned for H2 2027. stocktitan.net
- 5The dosing milestone triggers the closing of about $20 million in additional funding under the August 2025 equity private placement, bringing total proceeds to roughly $50 million. investing.com
- 6Equillium expects its cash and cash equivalents to fund planned operations through 2029. rttnews.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.